Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status-Reference-Cited by-同舟云学术

Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status

Published:2017-08-17 Issue:10 Volume:43 Page:1602-1612
ISSN:1341-8076
Container-title:Journal of Obstetrics and Gynaecology Research
language:en
Short-container-title:J. Obstet. Gynaecol. Res.

Author:

Yang Wen¹,Lu Yan-Ping¹,Yang Yi-Zhou¹,Kang Jia-Rui²,Jin Yi-Duo²,Wang Hong-Wei²^ORCID

Affiliation:

1. Department of Gynaecology and Obstetrics; General Hospital of People's Liberation Army; Beijing China

2. Department of Pathology; First Affiliated Hospital of General Hospital of People's Liberation Army; Beijing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Obstetrics and Gynaecology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jog.13411/fullpdf

Reference33 articles.

1. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia;Sheu;J Obstet Gynaecol Res,2007

2. Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity;Hebner;Rev Med Virol,2006

3. Structure and function of programmed death (PD) molecules;Folkl;Vet Immunol Immunopathol,2010

4. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses;Butte;Immunity,2007

5. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6;Li;J Exp Med,2011

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming growth factor-β micro-environment mediated immune cell functions in cervical cancer;International Immunopharmacology;2024-10

2. CDYL loss promotes cervical cancer aggression by increasing PD-L1 expression via the suppression of IRF2BP2 transcription;Translational Oncology;2024-09

3. Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer;Journal of Obstetrics and Gynaecology;2024-08-16

4. New Frontiers in Locally Advanced Cervical Cancer Treatment;Journal of Clinical Medicine;2024-07-30

5. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04);International Journal of Gynecologic Cancer;2024-06-10